Treatment for Molar Incisor Hypomineralization

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
School of Dentistry, University of Texas Health Science Center, San Antonio, TX
Molar Incisor Hypomineralization+1 More
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This study tests the remineralization of donor teeth (donorMIH) in situ in participants using 10% hydroxyapatite (HAP) toothpaste and sodium fluoride toothpaste.

Eligible Conditions

  • Molar Incisor Hypomineralization

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Molar Incisor Hypomineralization

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Baseline to 2 weeks

Baseline to 2 weeks
Change in mineral density (MD) of tooth

Trial Safety

Safety Progress

1 of 3

Other trials for Molar Incisor Hypomineralization

Trial Design

0 Treatment Group

15 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 2 weeks
Closest Location: School of Dentistry, University of Texas Health Science Center · San Antonio, TX
Photo of San Antonio  1Photo of San Antonio  2Photo of San Antonio  3
2016First Recorded Clinical Trial
1 TrialsResearching Molar Incisor Hypomineralization
1 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have no known history of allergy to personal care/consumer products.
You have at least 20 natural uncrowned teeth (excluding third molars).
You have a normal salivary flow rate.
You are able to consent.
You are available throughout the entire study.\n
You are willing to wear the appliance 24 hours per day.
You are willing to use only assigned products for oral hygiene for the duration of the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.